文献速递青光眼

选择性激光小梁成形术与药物治疗开角型青光眼的系统评价与Meta分析

Selective laser trabeculoplasty versus medication for open-angle glaucoma: systematic review and meta-analysis of randomised clinical trials.
PubMed 文献 · Br J Ophthalmol · 2020-02-12

该系统评价与Meta分析纳入8项随机对照试验共1229例开角型青光眼患者,比较选择性激光小梁成形术(SLT)相关治疗与单纯药物治疗的疗效。结果显示两组在眼压下降幅度和眼压控制成功率上无显著差异,但SLT相关治疗组所需降眼压药物显著更少。作者认为SLT安全且眼部副作用发生率更低,可作为开角型青光眼的一线治疗选择,但需考虑成本效益和患者特征。

要点

  • SLT相关治疗与单纯药物治疗在眼压下降和眼压控制成功率上无显著差异。
  • SLT相关治疗组所需降眼压药物显著少于单纯药物治疗组。
  • SLT安全且眼部副作用发生率更低,可考虑作为开角型青光眼一线治疗。

核心结论

  • SLT安全且眼部副作用发生率更低,可作为开角型青光眼的一线治疗选择。
  • 临床决策前应考虑成本效益以及患者特征。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Embase、Cochrane Library和Web of Science截至2019年8月的随机对照试验。
  • 纳入8项试验共1229例开角型青光眼患者,比较SLT相关治疗与单纯药物治疗。
  • 采用GRADE方法对证据体质量进行评级。

主要发现

  • SLT相关治疗与单纯药物治疗在眼压下降上无显著差异(MD:0.18,95%CI -0.72至1.07,p=0.70,I2=73%)。
  • 两组眼压控制成功率无显著差异(RR:1.02,95%CI 0.99至1.04,p=0.74,I2=0%)。
  • SLT相关治疗组所需药物显著少于单纯药物治疗组(MD:-1.06,95%CI -1.16至-0.96,p<0.0000,I2=5%)。
  • 因数据有限,未对不良事件和生活质量进行定量分析。

关键数值与推荐

  • 眼压下降的合并MD为0.18(95%CI -0.72至1.07,p=0.70,I2=73%)。
  • 眼压控制成功率的合并RR为1.02(95%CI 0.99至1.04,p=0.74,I2=0%)。
  • 所需药物数量的合并MD为-1.06(95%CI -1.16至-0.96,p<0.0000,I2=5%)。

临床怎么用

  • 可将SLT作为开角型青光眼的一线治疗选项之一。
  • 选择治疗方案时应结合成本效益和患者个体特征进行综合评估。

局限性

  • 不良事件和生活质量因数据有限未能进行定量分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The only widely accepted, effective treatment for open-angle glaucoma (OAG) is to reduce the intraocular pressure (IOP), with medical therapy being the typical first-line therapy. Notably, an alternative therapy is selective laser trabeculoplasty (SLT), which is safe and effective in lowering the IOP. Nonetheless, whether SLT could replace medication as the first-line therapy for OAG is still under debate. METHODS: Studies involving randomised controlled trials conducted before August 2019 that compared the efficacy of SLT-related and medication-only treatments for OAG were selected from PubMed, Embase, Cochrane Library and Web of Science. Grading of Recommendations, Assessment, Development and Evaluations (GRADE) methodology was employed to rate the quality of the body of evidence. RESULTS: 1229 patients in eight trials were included. The overall results revealed no significant differences between SLT-related and medication-only treatments regarding the IOP reduction (mean difference (MD): 0.18, 95% CI -0.72 to 1.07, p=0.70, I2=73%) and the success rate of IOP control (risk ratio: 1.02, 95% CI 0.99 to 1.04, p=0.74, I2=0%). The SLT-related therapy group required significantly fewer medications compared with the medication-only group (MD: -1.06, 95% CI -1.16 to -0.96, p<0.0000, I2=5%). A quantitative analysis was not performed concerning adverse events and quality of life because of the limited data available. CONCLUSION: SLT is safe and has a lower incidence of ocular side effects. SLT can be the choice of first-line therapy for OAG. However, clinicians should consider the cost-effectiveness, as well as the patient's characteristics, before deciding on the therapeutic option.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Chi SC, Kang YN, Hwang DK, et al. Selective laser trabeculoplasty versus medication for open-angle glaucoma: systematic review and meta-analysis of randomised clinical trials. Br J Ophthalmol. 2020. PMID: 32051136. doi:10.1136/bjophthalmol-2019-315613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。